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A recent study suggested that SLC35F3 which encoded a thiamine transporter was
a new candidate gene for hypertension. The goal of this study was to investigate
the association between the single-nucleotide polymorphisms (SNPs) in the SLC35F3
gene and hypertension in a Chinese population. Sanger sequencing was performed
in 93 samples to find SNPs in coding regions and intron–exon boundaries in the
SLC35F3 gene. We found eight genetic variants in the coding regions of SLC35F3
and subsequently genotyped a non-synonymous variant rs34032258 (C > G) in 1060
hypertension patients and 1467 controls. After adjusting for age and gender, multivariate
analysis of covariance showed that the variant was associated with hypertensive traits.
In detail, diastolic blood pressure (DBP) was 8 mmHg higher, blood urea nitrogen was
12 mmol/L higher, and creatinine was 15 mmol/L lower in G/G group compared with
C/C group (p = 0.007; 0.012 and 0.029, respectively). Further study suggested that
C/G+G/G had higher DBP than C/C genotype in those whose DBP ≥ 90 mmHg
(98.02 mmHg vs. 94.04 mmHg, p = 0.021). No significant difference has been found
in systolic blood pressure between different genotypes. Additionally, in the subgroup
of obesity, allele distribution of this variant has shown significant difference between
hypertensive patients and normotensive controls (p = 0.018). In conclusion, we found
that the rs34032258 in the SLC35F3 gene was associated with high blood pressure
and may increase the risk of hypertension. The new hypertension-susceptibility locus
may involve in the pathogenesis of hypertension and indicate some novel treatment
implications.
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INTRODUCTION
The prevalence of hypertension is increasing in most countries and hypertension is an
important risk factor for the development of cardiac-cerebral vascular diseases. However, the
cause still remains largely enigmatic (Evans et al., 2003; D’Agostino et al., 2008). Growing
evidence showed that genetic and environmental factors played a crucial role in the onset of
hypertension (Zhang et al., 2010; Munroe et al., 2011). According to single pressure value,
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the hypertensive heritability was 31–34%. In addition, average
value from more than three measurements showed a higher
heritability of 56–57% and it could reach as high as 63–68% based
on 24 h-ambulatory blood pressure monitory (Kupper et al.,
2006). The heritable trait remains the most potent and crucial risk
factor for cardiovascular diseases, although details of its genetic
determination are poorly understood (Munroe et al., 2011).
The solute carrier (SLC) group of transporters transports
organic or inorganic molecules across cell or organelle
membranes (Ishida et al., 2005; Zhang et al., 2012). Nearly
400 SLC members are organized into 52 families (Ishida and
Kawakita, 2004). Members of the human solute carrier 35
(SLC35) transporter family, which encode for nucleotide sugar
transporters, have been divided into six subfamilies (A–F; Ishida
and Kawakita, 2004; Saier et al., 2015)and are predominately
expressed in the lumen of the endoplasmic reticulum (ER)
and the Golgi apparatus (Goda et al., 2006). Genetic mutations
in SLC35 transporter family have been found associated with
cardiovascular diseases. In Zhang et al. (2014) have found the
SLC35F3 was associated with blood pressure in North America
and Western Europe. SLC35F3 sequence homolog to a putative
yeast thiamine (vitamin B1) transporter is located at 1q42.2
with 9 exons. The SLC35F3 mRNA was expressed at the highest
levels in the adult cerebellum (Nishimura et al., 2008). Up to
now, the effect of SLC35F3 genetic variants on blood pressure
has not been studied in Chinese populations. In this study,
we explored whether variants in the coding regions of the
SLC35F3 gene contributed to blood pressure variation and
hypertension.
MATERIALS AND METHODS
Subjects
We conducted a two-stage strategy in this study. First, we scanned
all the exons of SLC35F3 gene in 93 hypertensive patients by
Sanger sequencing. Subsequently, the most suspicious variants
were further genotyped by TaqMan-MGB assays in a total of
2527 participants, including 1060 hypertensive patients and 1467
normotensive controls. All of the participants were examined
at Shanghai Ruijin Hospital. Every participant signed a consent
form, and the study was approved by the hospital’s ethics
committee.
Age, gender, and medication usage were obtained from
Shanghai Institute of Hypertension, Ruijin hospital. Height
and weight were measured and BMI (kg/m2) was calculated.
Blood pressure was measured using a calibrated mercury
sphygmomanometer with appropriate adult cuff size by well-
trained examiners. Diagnosis of hypertension was based on a
mean SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg on two
occasions, and/or current usage of anti-hypertensive treatment.
Abbreviation: ANOVA, analysis of variance; BMI, body mass index; BP, blood
pressure; BUN, blood urea nitrogen; Cr, creatinine; DBP, diastolic blood pressure;
F, female; HR, heart rate; MAF, minor allele frequency; SBP, systolic blood
pressure; MANCOVA, multivariate analysis of covariance; SNP, single-nucleotide
polymorphism; TC, total cholesterol; TG, triglyceride; WC, waist circumference.
During different analytic processes, the samples selected were
diverse and the details are showed in Supplementary Table S1.
The characteristics of all the 2527 samples are showed in Table 1.
All the hypertensive patients (n = 1060) were selected in order
to analyze the effect of the SNP on hypertensive traits (Table 2).
Based on the results in Table 2, we selected 578 patients whose
DBP ≥ 90 mmHg to further verify the relationship between
the SNP and DBP (Figure 2). In addition, allelic frequencies of
rs34032258 in different BMI levels were analyzed between 1467
controls and 1035 cases excluding 25 unavailable BMI data in case
groups (Table 3). The effect of gender on SBP and DBP is shown
in Table 4 including all the participants. Besides, the plasma of
344 hypertensive patients was available for ELISA test in order
to verify the effect of this gene on blood thiamine in patients
(Figure 3).
DNA Samples
DNA was extracted from peripheral venous blood by lyzing red
blood cells (RBCs) and digesting the remaining white cell pellet
with proteinase K in accordance with the protocol (TIANamp
Genomic DNA kit, Tiangen, China). DNA samples were stored
at –80◦C until additional analysis was finished.
Selection and Genotyping of SLC35F3
Polymorphisms
Sanger sequencing of 9 exons of the SLC35F3 gene in 93 people
was performed by Mapbioo Technology Company of China.
Variant calling was carried out using Sequencher 5.1 and the
annotation of the detected variants was checked on National
Center for Biotechnology Information. We selected missense
variant and designed primers for further genotyping.
Genotypes were determined by pre-designed TaqMan
Allele Discrimination Assay (Cat. #4351379, primer
forward, 5′-AGCGTGCGTCACTGAATGA-3′; reverse, 5′-
ACACCCCCATGACTCAAGTG-3′, Life Technologies, USA).
TaqMan polymerase chain reaction (PCR) was performed on a
TABLE 1 | General characteristics of the study population.
Variables Controls (n = 1467) Cases (n = 1060) p
Gender (F/M) 764/703 522/538 0.160
Age (years) 63.11 ± 0.21 63.44 ± 0.16 0.236
Height (cm) 160.45 ± 0.20 162.59 ± 0.24 <0.001
Weight (kg) 58.87 ± 0.23 67.26 ± 0.31 <0.001
BMI (kg/m2) 22.85 ± 0.07 25.36 ± 0.09 <0.001
WC (cm) 80.26 ± 0.22 88.86 ± 0.26 <0.001
Hip (cm) 91.19 ± 0.15 96.31 ± 0.21 <0.001
SBP (mmHg) 115.50 ± 0.25 152.93 ± 0.57 <0.001
DBP (mmHg) 72.99 ± 0.18 91.41 ± 0.37 <0.001
TC (mmol/L) 4.85 ± 0.04 5.06 ± 0.11 0.031
TG (mmol/L) 1.46 ± 0.02 2.07 ± 0.19 0.002
BUN (mmol/L) 10.07 ± 0.44 11.62 ± 0.76 0.017
Cr (mmol/L) 70.18 ± 0.57 74.38 ± 1.03 <0.001
BMI, body mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure;
WC, waist circumference; BUN, blood urea uitrogen; F, female; M, male; Cr,
creatinine; TC, total cholesterol; TG, triglyceride. Statistically significant (p < 0.05).
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TABLE 2 | SLC35F3 variant rs34032258: effect on hypertensive traits in case group.
Genotype SBP (mmHg) DBP (mmHg) BUN (mmol/L) Cr (mmol/L) BMI (kg/m2)
CC (n = 991) 152.85 ± 0.60 91.26 ± 0.38 11.04 ± 0.78 74.47 ± 1.01 25.38 ± 0.10
CG (n = 48) 158.00 ± 2.55 93.70 ± 1.91 8.33 ± 0.85 79.22 ± 3.51 25.24 ± 0.46
GG (n = 21) 157.86 ± 4.09 99.14 ± 2.71 23.73 ± 7.38 59.59 ± 7.78 24.41 ± 0.55
p 0.096 0.007∗ 0.012∗ 0.029∗ 0.391
Effect of SLC35F3 variant rs34032258 on systolic blood pressure (SBP),diastolic blood pressure(DBP), blood urea nitrogen(BUN), Cr and body mass index(BMI) in case
group (n = 1060). Analysis of covariance (ANCOVA), adjusted for age and gender.*Statistically significant (p < 0.05).
TABLE 3 | Allelic frequencies of rs34032258 in different BMI levels.
Groups Allele OR p
C G
Underweight Cases (n = 8) 16 (1.000) 0 (0.000) 0.291
Controls (n = 107) 200 (0.935) 14 (0.065)
Normal Cases (n = 228) 433 (0.949) 23 (0.051) 0.799 0.375
Controls (n = 688) 1320 (0.959) 56 (0.041)
Overweight Cases (n = 245) 470 (0.959) 20 (0.041) 0.762 0.393
Controls (n = 334) 647 (0.969) 21 (0.031)
Obese Cases (n = 554) 1061 (0.958) 47 (0.042) 1.344 0.018∗
Controls (n = 338) 638 (0.944) 38 (0.056)
BMI was layered according to local related guide in 2010 released by China health department. Underweight: BMI < 18.5; normal: 18.5 ≤ BMI<23; overweight:
23 ≤ BMI<25; obese: BMI ≥ 25. Case: n = 1035; control: n = 1467; Missed data in case was 25.*Statistically significant (p < 0.05).
TABLE 4 | The effect of gender on SBP and DBP.
Gender SBP (mmHg) p DBP (mmHg) p
Total Male 131.22 ± 0.65 0.863 82.83 ± 0.39 <0.000∗
Female 131.37 ± 0.68 78.78 ± 0.36
Cases Male 152.35 ± 0.76 0.145 93.57 ± 0.52 <0.000∗
Female 154.04 ± 0.87 89.43 ± 0.52
Controls Male 115.91 ± 0.35 0.089 74.62 ± 0.25 <0.000∗
Female 115.05 ± 0.35 71.50 ± 0.27
One-way ANOVA was used to analyze between BP and sex in different groups. *Statistically significant (p < 0.05).
7900 Real-Time PCR system (Applied Biosystems, Foster City,
CA, USA) in total volume of 2.5 µL consisting of 2.4 µL TaqMan
PCR Master Mix (Life Technologies, USA) and 0.03 µL genomic
DNA. Cycling conditions were 95◦C for 30 s, and 50 cycles of
95◦C for 15 s, and 60◦C for 1 min.
Measurement of Thiamine B1
Thiamine B1 concentration was determined by using ELISA kit
(E-EL-0007c, Elabscience).
Statistical Analysis
Continuous variables expressed as mean ± standard error (SE)
were compared between two groups by unpaired t-test. Relations
between categorical variables were examined by χ2 test. The
association of examined SNPs with hypertension as a binary trait
and BP as a continuous trait was done by Logistic and linear
regression analyses, respectively, after adjusting for age, gender,
and BMI. MANCOVA was used to compare the differences
of BP, BMI, BUN, and Cr across the genotypes of rs34032258
after treating age and gender as covariates. The frequencies of
genotypes between patients and controls were estimated by SHE1.
Considering the impact of antihypertensive regimens, SBP and
DBP were added by a fixed value of 10 and 5 mmHg, respectively,
according to a previous report (Cui et al., 2003). BMI was
classified according to the guidelines released by the Ministry
of Health of China in 2010. Statistical analyses were performed
with SPSS version 13.0 for Windows. Two-sided p < 0.05 was
considered to be significant.
RESULTS
rs34032258 Missense Variant Detected in
93 Samples by Sanger Sequencing
In 93 hypertension patients, eight genetic variants were found in
the coding regions of SLC35F3. Among them, a missense variant,
1http://analysis.bio-x.cn/SHEsisMain.htm
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FIGURE 1 | Typical sequences of specific mutations in the SLC35F3
SNPs in hypertensive patients. (A) Rs16842784 was not found mutation in
Chinese people. (B) C > G mutation in rs34032258.
FIGURE 2 | DBP level between G-carriers and wild type in those whose
DBP ≥ 90 mmHg. n = 578, p = 0.021.
rs34032258, was detected with an allele frequency of 3.73%
(Figure 1B, 466C > G). However, SNPs previously reported to
be associated with hypertension, either rs16842784 or rs17514104
was not found in the 93 samples (Figure 1A).
Baseline Characteristics
The comparisons of the demographic and clinical features
between hypertensive patients and normotensive controls are
shown in Table 1. The distributions of age (p = 0.16) and
gender (p = 0.24) did not differ significantly between patients
and controls. BMI (p < 0.001), blood pressures (both p < 0.001)
FIGURE 3 | SLC35F3 genotypes effect on blood thiamine in patients.
C/C genotype: n = 344; C/G +G/G genotype: n = 14, p = 0.551.
and Cr were significantly higher in patients than in controls as
expected.
Association of rs34032258 with
Hypertension in Han Chinese
The associations of rs34032258 with BP, BMI, BUN, and Cr
are shown in Table 2. After adjusting for age and gender, the
result from MANCOVA showed that rs34032258 was associated
with DBP, BUN, and Cr. In detail, DBP was 8 mmHg higher,
BUN was 12 mmol/L higher, and Cr was 15 mmol/L lower in
G/G group compared with C/C group. In contrast, there was no
difference in SBP and BMI between the two groups. Further study
suggested that C/G+G/G had higher DBP than C/C genotype in
those whose DBP ≥ 90 mmHg (98.02 mmHg vs. 94.04 mmHg,
p = 0.021; Figure 2). Notably, we found that G allele frequency
was significantly lower in hypertensive patients compared with
controls in obesity group (OR = 1.34, p = 0.018; Table 3). No
significant difference was found between controls and cases in
underweight, normal weight, or overweight subjects.
We also performed logistic regression analysis to assess
the association between hypertension and rs34032258 after
adjusting confounding factors such as age, gender, and BMI.
The result exhibited that compared to C/C genotype, C/G and
G/G genotypes were not statistically associated with the risk of
hypertension, with the corresponding odds ratio of being 1.18
(95% CI: 0.64–2.12) and 1.25 (95% CI: 0.60–2.52), respectively
(both p > 0.05). Moreover, we examined the association of
rs34032258 with SBP and DBP on a continuous scale by using
linear regression analysis with age, gender, and BMI as covariates,
and as expected, this variant was significantly associated with SBP
and DBP (p= 0.033 and 0.010), especially for the latter (data not
shown).
To discover the relation between sex and BP, one-way ANOVA
analysis was performed and the result showed that male had
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higher DBP both in case group (93.57 mmHg vs. 89.43 mmHg,
p < 0.000; Table 4) and in control group (74.62 mmHg vs.
71.50 mmHg, p < 0.000; Table 4).
No significant difference was detected in Thiamine
B1 concentration between rs34032258 genotypes (C/C
5.40 ± 2.19 mmol/L vs. C/G+G/G 4.92 ± 2.82 mmol/L,
p= 0.551; Figure 3).
DISCUSSION
Zhang et al. (2014) found that rs17514104 and rs16842784 in the
SLC35F3 gene were associated with BP in subjects from North
America and Western Europe, through the use of phenotypic
extremes and genomic DNA pooling (Zhang et al., 2014).
However, we detected neither rs17514104 nor rs16842784 in 93
Chinese people, because allele frequency might be variable in
different ethnic population.
We found that rs34032258 was associated with DBP, BUN
and Cr, but not with SBP, BMI. This finding was consistent with
previous studies showing that DBP but not SBP was substantially
heritable (Snieder et al., 2003; Kupper et al., 2005). In addition,
in those patients whose DBP ≥ 90 mmHg, G-carriers had higher
DBP. This finding indicated that SLC35F3 may be associated with
the regulation of BP and kidney function. We did not observe any
association between rs34032258 and BMI. However, we found
that there was a lower frequency of G allele of rs34032258 in
cases compared with normotensive controls in obesity group.
This result suggested that rs34032258 may be involved in obesity-
related hypertension.
SLC35F3 encoded vitamin B1 transporter. According to the
prediction using online software2, the mutation of SLC35F3 in
rs34032258 (Supplement Figure S1) induced the loose of protein
tertiary structure of vitamin B1 transporter, then probably
decreased the concentration of vitamin B1 in plasma.
Vitamin B1, a water-soluble vitamin, played an important
role in intracellular glucose metabolism. As a coenzyme
for α-ketoglutarate-dehydrogenase, it was implicated in the
tricarboxylic acid (TCA) cycle, catalyzing the oxidation of
ketoglutaric acid to succinyl-CoA. In addition, it was a coenzyme
for the pyruvate dehydrogenase complex (PDHC), converting
pyruvate to acetyl-CoA. Clinical studies have shown that vitamin
B1 might be associated with cardiovascular diseases (Wilkinson
et al., 1997). Vitamin B1 supplementation was reported to reduce
blood pressure, especial in patients combined with hyperglycemia
(Alaei-Shahmiri et al., 2015). In accordance with the result,
thiamine repletion could relieve the symptoms of hypertension
and hyperinsulinemia in spontaneously hypertensive rats (SHR;
Tanaka et al., 2007). However, the underlying mechanisms are
still unknown.
One of the mechanisms might be that vitamin B1 could
ameliorate the endothelium-dependent vasodilation (Subodh
Arora et al., 2006). Routine administration of thiamine
might improve endothelial function and therefore slowed
2http://raptorx.uchicago.edu/
the progression of atherosclerosis, especially in patients with
impaired glucose tolerance (IGT) who were prone to develop
accelerated atherosclerosis (Subodh Arora et al., 2006). The
SLC35F3 mutation could result in the shortage of vitamin B1,
then increased the blood pressure.
In addition, vitamin B1 might be related to the cardiac
function (Han et al., 1995). Reduction of vitamin B1 was found to
be involved the accumulation of intermediate products in glucose
metabolism such as pyruvic acid and lactic acid, which could
stimulate expansion of peripheral arterial, reduce peripheral
resistance, and increase venous return, cardiac output and blood
pressure (Zenuk et al., 2003).
The present study may have some limitations. Although
our study sample size was considerable, we might not
be powerful enough to capture some potential rare but
functional causal variants in the SLC35F3 gene. These disease-
causing variants could be in linkage disequilibrium with
rs34032258.
In summary, this study is the first to report the association
between a missense variant, rs34032258, in the SLC35F3 gene
and hypertension in a Chinese Han population. Further study
is needed to discover the molecular mechanisms of SLC35F3 to
blood pressure in order to improve clinical treatment. Our results
may have implications for the pathogenesis and treatment of
systemic hypertension.
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